Date:11/9/2009

661 Restricted cash 916 3,629 Accounts receivable, net 263,231 321,299 Inventories 182,780 174,667 Deferred income tax assets 52,165 53,660 Prepaid expenses and other current assets 29,238 44,662 ------ ------ Total current assets 821,516 693,578 ------- ------- Property and equipment, net 271,628 283,975 Intangible assets, net 2,424,812 2,629,651 Goodwill 2,108,963 4,450,496 Other assets 62,909 76,932 ------ ------ $5,689,828 $8,134,632 ========== ========== LIABILITIES AND STOCKHOLDERS' EQUITY September 26, September 27, 2009 2008 ---- ---- CURRENT LIABILITIES: Current portion of notes payable $38,373 $38,480 Accounts payable 46,589 59,590 Accrued expenses 137,284 154,746 Deferred revenue 97,544 78,559 Deferred gain 9,500 9,500 ----- ----- Total current liabilities 329,290
'/>"/>

SOURCE Hologic, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients